Novo Nordisk, the manufacturer of brand-name semaglutide, has taken legal action against several businesses for selling inferior compounded versions of the drug
Because retatrutide has a 6-day half-life, the drug does not disappear quickly after stopping
Further study (103) has revealed that its anti-inflammatory and immunomodulatory effects may be related to the inhibition of the activation of MAPK signaling pathways (JNK, ERK1/2 and p38)
Bottom line: Tirzepatide became available for diabetes in May 2022 and for weight loss in November 2023, offering a new dual-action approach to metabolic health
Dual Eligible Special Needs Plans (D-SNPs), one type of SNP, enroll only individuals dual eligible for Medicare and Medicaid
These are most likely due to the weight loss itself rather than some other independent factor